Lucid Diagnostics Inc (LUCD)

Name: Lucid Diagnostics Inc (LUCD) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Lucid Diagnostics Inc (LUCD)

Stock Card

$0.99

$0.02 (2.00%)

As on 27-Aug-2026 15:36EDT

Market cap

$184 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

P/B Ratio

16.8

Div. Yield

0 %

Lucid Diagnostics Inc (LUCD) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.96 High: 1.02

52 Week Range

Low: 0.86 High: 1.63

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.6 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

-0.7
Debt to Equity

0
Book Value

$--
EPS

$-0.5
Face value

--
Shares outstanding

190,948,730

6 Years Aggregate

CFO

$-88.33 Mln

EBITDA

$-140.33 Mln

Net Profit

$-150.27 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Lucid Diagnostics Inc (LUCD)	-9.2	9.1	-10.8	-16.1	-12.5	--	--
BSE Sensex	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Lucid Diagnostics Inc (LUCD)	33.1	-41.7	3.7	-74.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Lucid Diagnostics Inc (LUCD)	1.0	184.1	5.5	-52.3	-959.4	-478.1	--	16.8
10X Genomics Inc (TXG)	64.6	8,484.6	616.9	-75.1	1.7	-9.3	--	10.1
Avantor (AVTR)	14.6	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	59.4	9,074.5	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	181.5	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	100.8	6,525.3	1,556.3	275.3	24.6	22.9	24	5.0
Penumbra (PEN)	321.7	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	182.6	10,222.2	785.1	41.5	9.9	2	251.6	4.8
Smith & Nephew SNATS - ADR	29.2	12,153.4	6,164.0	625.0	13.0	11.8	19.9	2.4

Shareholding Pattern

View Details

About Lucid Diagnostics Inc (LUCD)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer,... primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. Read more

Chairman & CEO

Dr. Lishan Aklog M.D.
Chairman & CEO

Dr. Lishan Aklog M.D.
Headquarters

New York, NY
Website

https://www.luciddx.com

FAQs for Lucid Diagnostics Inc (LUCD)

What is the current share price of Lucid Diagnostics Inc (LUCD) Today?

The share price of Lucid Diagnostics Inc (LUCD) is $0.99 (NASDAQ) as of 27-Aug-2026 15:36 EDT. Lucid Diagnostics Inc (LUCD) has given a return of -12.54% in the last 3 years.

What is the current PB & PE ratio of Lucid Diagnostics Inc (LUCD)?

Since, TTM earnings of Lucid Diagnostics Inc (LUCD) is negative, P/E ratio is not available.
The P/B ratio of Lucid Diagnostics Inc (LUCD) is 16.78 times as on 21-Aug-2026, a 337 premium to its peers’ median range of 3.84 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-1.92	10.16
2024	-1.04	8.76
2023	-1.12	-25.48
2022	-0.90	2.20
2021	-6.68	3.43

What is the 52 Week High and Low of Lucid Diagnostics Inc (LUCD)?

The 52-week high and low of Lucid Diagnostics Inc (LUCD) are Rs 1.63 and Rs 0.86 as of 28-Aug-2026.

What is the market cap of Lucid Diagnostics Inc (LUCD)?

Lucid Diagnostics Inc (LUCD) has a market capitalisation of $ 184 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Lucid Diagnostics Inc (LUCD)?

Before investing in Lucid Diagnostics Inc (LUCD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.